Latest & greatest articles for epilepsy

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on epilepsy or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on epilepsy and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for epilepsy

501. Acupuncture for epilepsy. (Abstract)

Acupuncture for epilepsy. Seizures are poorly controlled in many people with epilepsy despite adequate current antiepileptic treatments. There is increasing interest in alternative therapies such as acupuncture; however, it remains unclear whether the existing evidence is rigorous enough to support the use of acupuncture.To determine the effectiveness and safety of acupuncture in people with epilepsy.We searched the Cochrane Epilepsy Group's Specialized Register (June 2005) and the Cochrane (...) of acupuncture involving people of any age with any type of epilepsy were included. Trials included were those comparing acupuncture with placebo, sham or no treatment; or comparing acupuncture plus other treatments with the same other treatments. Trials that only compared different acupuncture methods or compared acupuncture alone with other treatments were excluded.Two review authors independently extracted trial data and assessed trial quality using the Jadad score. Relative risk (RR) was used for binary

2006 Cochrane

502. Adult epilepsy. (Abstract)

Adult epilepsy. The epilepsies are one of the most common serious brain disorders, can occur at all ages, and have many possible presentations and causes. Although incidence in childhood has fallen over the past three decades in developed countries, this reduction is matched by an increase in elderly people. Monogenic Mendelian epilepsies are rare. A clinical syndrome often has multiple possible genetic causes, and conversely, different mutations in one gene can lead to various epileptic (...) syndromes. Most common epilepsies, however, are probably complex traits with environmental effects acting on inherited susceptibility, mediated by common variation in particular genes. Diagnosis of epilepsy remains clinical, and neurophysiological investigations assist with diagnosis of the syndrome. Brain imaging is making great progress in identifying the structural and functional causes and consequences of the epilepsies. Current antiepileptic drugs suppress seizures without influencing

2006 Lancet

503. Recessive symptomatic focal epilepsy and mutant contactin-associated protein-like 2. (Abstract)

Recessive symptomatic focal epilepsy and mutant contactin-associated protein-like 2. Contactin-associated protein-like 2 (CASPR2) is encoded by CNTNAP2 and clusters voltage-gated potassium channels (K(v)1.1) at the nodes of Ranvier. We report a homozygous mutation of CNTNAP2 in Old Order Amish children with cortical dysplasia, focal epilepsy, relative macrocephaly, and diminished deep-tendon reflexes. Intractable focal seizures began in early childhood, after which language regression

2006 NEJM

504. Epilepsy in children. (Abstract)

Epilepsy in children. 10.5 million children worldwide are estimated to have active epilepsy. Over the past 15 years, syndrome-oriented clinical and EEG diagnosis, and better aetiological diagnosis, especially supported by neuroimaging, has helped to clarify the diversity of epilepsy in children, and has improved management. Perinatal and postinfective encephalopathy, cortical dysplasia, and hippocampal sclerosis account for the most severe symptomatic epilepsies. Ion channel defects can (...) known, and there is heightened awareness that compounds with severe cognitive side-effects and heavy polytherapies should be avoided. Epilepsy surgery is an important option for a few well-selected individuals, but should be considered with great caution when there is no apparent underlying brain lesion.

2006 Lancet

505. The clinical effectiveness and cost-effectiveness of newer drugs for children with epilepsy: a systematic review

The clinical effectiveness and cost-effectiveness of newer drugs for children with epilepsy: a systematic review The clinical effectiveness and cost-effectiveness of newer drugs for children with epilepsy: a systematic review The clinical effectiveness and cost-effectiveness of newer drugs for children with epilepsy: a systematic review Connock M, Frew E, Evans B W, Bryan S, Cummins C, Fry-Smith A, Li Wan Po A, Sandercock J CRD summary The review identified very few studies that compared (...) the effectiveness of newer antiepileptic drugs to standard drug treatments in children; most studies were placebo-controlled trials conducted to establish effectiveness for licensing purposes. The authors concluded appropriately that there was insufficient information to develop an evidence-based prescribing strategy for newer antiepileptic drugs in children with epilepsy of any type. Authors' objectives To assess the clinical and cost effectiveness of newer antiepileptic drugs used in monotherapy or as add

2006 DARE.

506. The role of 1H magnetic resonance spectroscopy in pre-operative evaluation for epilepsy surgery: a meta-analysis

The role of 1H magnetic resonance spectroscopy in pre-operative evaluation for epilepsy surgery: a meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2006 DARE.

507. A systematic review of the effectiveness and cost-effectiveness of neuroimaging assessments used to visualise the seizure focus in people with refractory epilepsy being considered for surgery

A systematic review of the effectiveness and cost-effectiveness of neuroimaging assessments used to visualise the seizure focus in people with refractory epilepsy being considered for surgery A systematic review of the effectiveness and cost-effectiveness of neuroimaging assessments used to visualise the seizure focus in people with refractory epilepsy being considered for surgery A systematic review of the effectiveness and cost-effectiveness of neuroimaging assessments used to visualise (...) the seizure focus in people with refractory epilepsy being considered for surgery Whiting P, Gupta R, Burch J, Mujica Mota R E, Wright K, Marson A, Weishmann U, Haycox A, Kleijnen J, Forbes C Citation Whiting P, Gupta R, Burch J, Mujica Mota R E, Wright K, Marson A, Weishmann U, Haycox A, Kleijnen J, Forbes C. A systematic review of the effectiveness and cost-effectiveness of neuroimaging assessments used to visualise the seizure focus in people with refractory epilepsy being considered for surgery

2006 Health Technology Assessment (HTA) Database.

508. The clinical effectiveness and cost-effectiveness of newer drugs for children with epilepsy: a systematic review

The clinical effectiveness and cost-effectiveness of newer drugs for children with epilepsy: a systematic review The clinical effectiveness and cost-effectiveness of newer drugs for children with epilepsy: a systematic review The clinical effectiveness and cost-effectiveness of newer drugs for children with epilepsy: a systematic review Connock M, Frew E, Evans B-W, Bryan S, Cummins C, Fry-Smith A, Li Wan Po A, Sandercock J Record Status This is a bibliographic record of a published health (...) technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Connock M, Frew E, Evans B-W, Bryan S, Cummins C, Fry-Smith A, Li Wan Po A, Sandercock J. The clinical effectiveness and cost-effectiveness of newer drugs for children with epilepsy: a systematic review. Health Technology Assessment 2006; 10(7): 1-134 Authors' objectives The aim of this review is to examine the clinical effectiveness and cost-effectiveness of newer

2006 Health Technology Assessment (HTA) Database.

509. Vagus Nerve Stimulation for refractory epilepsy

Vagus Nerve Stimulation for refractory epilepsy Vagus Nerve Stimulation for refractory epilepsy Vagus Nerve Stimulation for refractory epilepsy Pichon Riviere A, Augustovski F, Alcaraz A, Bardach A, Ferrante D, Garcia Marti S, Glujovsky D, Lopez A, Regueiro A Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Pichon Riviere A, Augustovski F (...) , Alcaraz A, Bardach A, Ferrante D, Garcia Marti S, Glujovsky D, Lopez A, Regueiro A. Vagus Nerve Stimulation for refractory epilepsy. Buenos Aires: Institute for Clinical Effectiveness and Health Policy (IECS). Informe de Respuesta Rapida No.90. 2006 Authors' objectives The objective of the report was to assess the use of VNS for the treatment of patients with refractory epilepsy. Authors' conclusions Although VNS can lessen the number of seizures in some patients, there is no evidence to indicate

2006 Health Technology Assessment (HTA) Database.

510. Phenobarbital for childhood epilepsy: systematic review

Phenobarbital for childhood epilepsy: systematic review Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2006 DARE.

511. Psychological treatments for epilepsy. (Abstract)

Psychological treatments for epilepsy. Psychological interventions such as relaxation therapy, cognitive behaviour therapy, bio-feedback and educational interventions have been used alone or in combination in the treatment of epilepsy, to reduce the seizure frequency and improve the quality of life.To assess whether the treatment of epilepsy with psychological methods is effective in reducing seizure frequency and/or leads to a better quality of life.We searched the Cochrane Epilepsy Group's (...) for inclusion and extracted data. Primary analyses were by intention to treat. Outcomes included reduction in seizure frequency and quality of life.We found three small trials (50 participants) of relaxation therapy. They were of poor methodological quality and a meta-analysis was therefore not undertaken. No study found a significant effect of relaxation therapy on seizure frequency. One trial found cognitive behavioural therapy to be effective in reducing depression, among people with epilepsy

2005 Cochrane

512. Risk for schizophrenia and schizophrenia-like psychosis among patients with epilepsy: population based cohort study. Full Text available with Trip Pro

Risk for schizophrenia and schizophrenia-like psychosis among patients with epilepsy: population based cohort study. To investigate whether age at onset of epilepsy, type of epilepsy, family history of psychosis, or family history of epilepsy affect the risk of schizophrenia or schizophrenia-like psychosis among patients with epilepsy.Comparison of population based data.Danish longitudinal registers.The cohort comprised 2.27 million people.Epilepsy, psychosis, personal birth data.We found (...) an increased risk of schizophrenia (relative risk 2.48, 95% confidence interval 2.20 to 2.80) and schizophrenia-like psychosis (2.93, 2.69 to 3.20) in people with a history of epilepsy. The effect of epilepsy was the same in men and in women and increased with age. Family history of psychosis and a family history of epilepsy were significant risk factors for schizophrenia and schizophrenia-like psychosis, and the effect of epilepsy, both in cases and families, was greater among people with no family

2005 BMJ

513. Immediate versus deferred antiepileptic drug treatment for early epilepsy and single seizures: a randomised controlled trial. (Abstract)

Immediate versus deferred antiepileptic drug treatment for early epilepsy and single seizures: a randomised controlled trial. The relative risks and benefits of starting or withholding antiepileptic drug treatment in patients with few or infrequent seizures are unclear. We sought to compare policies of immediate versus deferred treatment in such patients and to assess the effects of these policies on short-term recurrence and long-term outcomes.We undertook an unmasked, multicentre, randomised (...) study of immediate and deferred antiepileptic drug treatment in 1847 patients with single seizures and early epilepsy. Outcomes comprised time to first, second, and fifth seizures; time to 2-year remission; no seizures between years 1 and 3 and between years 3 and 5 after randomisation; and quality of life. Analysis was by intention to treat.404 patients invited to join the trial did not consent to randomisation; 722 were subsequently assigned immediate treatment with antiepileptic drugs and 721

2005 Lancet Controlled trial quality: predicted high

514. Assessing the cost-effectiveness of new pharmaceuticals in epilepsy in adults: the results of a probabilistic decision model

Assessing the cost-effectiveness of new pharmaceuticals in epilepsy in adults: the results of a probabilistic decision model Assessing the cost-effectiveness of new pharmaceuticals in epilepsy in adults: the results of a probabilistic decision model Assessing the cost-effectiveness of new pharmaceuticals in epilepsy in adults: the results of a probabilistic decision model Hawkins N, Epstein D, Drummond M, Wilby J, Kainth A, Chadwick D, Sculpher M Record Status This is a critical abstract (...) of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Treatments for epilepsy were examined in adults in three situations: monotherapy for newly diagnosed patients, monotherapy for refractory patients, and combination therapy for refractory patients. Since the analysis separately

2005 NHS Economic Evaluation Database.

515. Economic evaluation of levetiracetam as an add-on therapy in patients with refractory epilepsy

Economic evaluation of levetiracetam as an add-on therapy in patients with refractory epilepsy Economic evaluation of levetiracetam as an add-on therapy in patients with refractory epilepsy Economic evaluation of levetiracetam as an add-on therapy in patients with refractory epilepsy Sheehy O, St-Hillaire J M, Bernier G, Godfroid P, LeLorier J Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief (...) summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of levetiracetam (LEV), a new antiepileptic agent, plus standard therapy (ST) for patients with refractory epilepsy. Three different dosage of levetiracetam were considered, 1,000 mg/day, 2,000 mg/day and 3,000 mg/day. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population The study

2005 NHS Economic Evaluation Database.

516. Clinical effectiveness, tolerability and cost-effectiveness of newer drugs for epilepsy in adults: a systematic review and economic evaluation

Clinical effectiveness, tolerability and cost-effectiveness of newer drugs for epilepsy in adults: a systematic review and economic evaluation Clinical effectiveness, tolerability and cost-effectiveness of newer drugs for epilepsy in adults: a systematic review and economic evaluation Clinical effectiveness, tolerability and cost-effectiveness of newer drugs for epilepsy in adults: a systematic review and economic evaluation Wilby J, Kainth A, Hawkins N, Epstein D, McIntosh H, McDaid C, Mason (...) ' objectives To assess the clinical effectiveness, tolerability and cost effectiveness of newer drugs for epilepsy in adults. Searching The Cochrane Library, DARE, HTA database, MEDLINE, EMBASE, PsycINFO, NRR, Science Citation Index, Index to Scientific and Technical Proceedings and a range of internet resources, including national guidelines websites, were searched from inception to dates in 2002. The bibliographies of included articles and pharmaceutical industry submissions were reviewed for further

2005 DARE.

517. Clinical effectiveness, tolerability and cost-effectiveness of newer drugs for epilepsy in adults: a systematic review and economic evaluation

Clinical effectiveness, tolerability and cost-effectiveness of newer drugs for epilepsy in adults: a systematic review and economic evaluation Clinical effectiveness, tolerability and cost-effectiveness of newer drugs for epilepsy in adults: a systematic review and economic evaluation Clinical effectiveness, tolerability and cost-effectiveness of newer drugs for epilepsy in adults: a systematic review and economic evaluation Wilby J, Kainth A, Hawkins N, Epstein D, McIntosh H, McDaid C, et al (...) Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Wilby J, Kainth A, Hawkins N, Epstein D, McIntosh H, McDaid C, et al. Clinical effectiveness, tolerability and cost-effectiveness of newer drugs for epilepsy in adults: a systematic review and economic evaluation. Health Technology Assessment 2005; 9(15): 1-172 Authors' objectives The aim

2005 Health Technology Assessment (HTA) Database.

518. Loss of glutamine synthetase in the human epileptogenic hippocampus: possible mechanism for raised extracellular glutamate in mesial temporal lobe epilepsy. (Abstract)

Loss of glutamine synthetase in the human epileptogenic hippocampus: possible mechanism for raised extracellular glutamate in mesial temporal lobe epilepsy. High extracellular glutamate concentrations have been identified as a likely trigger of epileptic seizures in mesial temporal lobe epilepsy (MTLE), but the underlying mechanism remains unclear. We investigated whether a deficiency in glutamine synthetase, a key enzyme in catabolism of extracellular glutamate in the brain, could explain

2004 Lancet

519. Vagus nerve stimulation for refractory epilepsy in children (IPG50)

Vagus nerve stimulation for refractory epilepsy in children (IPG50) Overview | Vagus nerve stimulation for refractory epilepsy in children | Guidance | NICE Vagus nerve stimulation for refractory epilepsy in children Interventional procedures guidance [IPG50] Published date: March 2004 Share Save Guidance NICE has now issued full guidance to the NHS in England, Wales, Scotland and Northern Ireland on vagus nerve stimulation for refractory epilepsy in children. Description Vagus nerve (...) stimulation is used in children and adults with epilepsy, particularly complex partial epilepsy that remains incapacitating despite maximal anti-epileptic medication. The technique has also been used in children with medically refractory encephalopathic seizures, idiopathic seizures, primary generalised epilepsy and the Lennox-Gastaut syndrome, which is a young onset epileptic disorder characterised by multiple seizures types and developmental delay. Epilepsy prevalence is 2% to 5% worldwide (World Health

2004 National Institute for Health and Clinical Excellence - Interventional Procedures

520. Vagus nerve stimulation for refractory epilepsy in children

Vagus nerve stimulation for refractory epilepsy in children Vagus nerve stimulation for refractory epilepsy in children Vagus nerve stimulation for refractory epilepsy in children National Institute for Clinical Excellence Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation National Institute for Clinical Excellence. Vagus nerve stimulation for refractory epilepsy (...) in children. London: National Institute for Clinical Excellence (NICE) 2004: 2 Authors' objectives This study aims to assess the current evidence on the safety and efficacy of vagus nerve stimulation for refractory epilepsy in children. Authors' conclusions 1.1 Current evidence on the safety and efficacy of vagus nerve stimulation for refractory epilepsy in children appears adequate to support the use of this procedure, provided that the normal arrangements are in place for consent, audit and clinical

2004 Health Technology Assessment (HTA) Database.